Cipla shares: USFDA Ventolin nod, 2026 outlook

Stock reaction stays mixed despite a key USFDA clearance

Cipla Ltd’s shares traded with mixed cues after its US arm received final approval from the United States Food and Drug Administration (USFDA) for a generic version of Ventolin HFA, a widely used asthma inhaler. In one market snapshot, the stock slipped 1.27% to ₹1,289.30 on the NSE even as the regulatory update was in focus. The day’s trading range in that session was wide, with an intraday high of ₹1,295 and a low of ₹1,254.10. Turnover crossed ₹217 crore and about 17.06 lakh shares changed hands, with buy orders at 54% of traded quantity versus 46% sell orders.

Other reports from April 23, 2026 described a sharper intraday rise, with the stock trading around ₹1,274.40, up 3.08% as of 10:54 IST versus a previous close of ₹1,236.30. Another update said the stock opened around ₹1,236 and moved to about ₹1,287 by noon, with an intraday range cited around ₹1,232 to ₹1,295. Taken together, the price action signalled that investors were balancing the positive impact of a complex generic approval against near-term earnings visibility and execution risks in the US business.

Underperformance versus Nifty keeps pressure on sentiment

The approval came at a time when Cipla has lagged the broader market. The stock is down 14.36% in 2026 so far and has fallen 17.17% over the past year, while the Nifty 50 index slipped 1.21% over the same period. Cipla’s 52-week high of ₹1,673 was recorded in October 2025, while a 52-week low of ₹1,165.70 was touched on April 2.

Separately, another market update cited a 9-month low near ₹1,367.80 during a different session after the company flagged a supply disruption risk around Lanreotide. That report also cited a 52-week low of ₹1,310.05 on April 7, 2025 and a 52-week high near ₹1,672.20 on October 23, 2025. The takeaway for investors is that the Ventolin approval is landing amid an already sensitive backdrop for the US portfolio.

What the USFDA approved and why it matters

Cipla USA Inc. received final USFDA approval for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. The product is described as the first AB-rated generic therapeutic equivalent of GlaxoSmithKline’s Ventolin HFA. An AB rating indicates therapeutic equivalence to the branded product, allowing pharmacist substitution in the United States subject to state laws.

Cipla said the inhaler will be produced at its dedicated inhalation facility in Fall River, Massachusetts. The company plans to launch the product in the first half of FY2026-27. The US albuterol market is pegged at about $1,500 million, based on IQVIA data cited in a company update.

Launch timing and the US respiratory strategy

The planned H1 FY2026-27 launch gives the market a defined window, but it also pushes near-term financial impact into FY27. Brokerages generally framed the approval as supportive for Cipla’s US respiratory franchise, particularly in inhalation products where device complexity can limit competition. Some reports also noted that Cipla has approved generics for both Ventolin HFA and Proventil HFA, strengthening its presence across albuterol device profiles.

The approval has also been read as a sentiment reset for Cipla’s complex generics execution, given that delays in the past, including products like generic Advair, had weighed on investor confidence. Still, the Street commentary shows that optimism on the product is being balanced against pipeline delivery and the earnings impact of other US headwinds.

Broker calls: Underweight to Buy, with different assumptions

Morgan Stanley retained an Underweight rating on Cipla while raising its target price to ₹1,237 from ₹1,211. The brokerage values the Ventolin HFA generic at $130 million in FY27 sales and expects about a 4% lift to earnings per share. It also flagged that gains from the albuterol launch could partly offset pressure on Lanreotide sales and support the respiratory portfolio, but reiterated that execution remains a key risk.

Citi maintained a Buy rating with a target price of ₹1,530. Citi expects $10 million to $10 million in annual revenue contribution and argued that the approval helps rebuild confidence, especially as it may offset potential weakness in the US business tied to Lanreotide-related disruption.

ICICI Securities upgraded the stock to ‘Buy’ from ‘Add’ and raised the target price to ₹1,550 from ₹1,450, citing a pipeline of eight respiratory drugs including gAdvair, gSymbicort and gQvar, alongside peptide assets such as gVictoza. MOFSL maintained a Neutral rating with a target price of ₹1,307 and pointed to Cipla’s earlier albuterol launch scale-up as a positive indicator for commercialisation.

Lanreotide disruption remains a parallel overhang

The Ventolin approval has coincided with ongoing focus on Lanreotide, described in the reports as one of Cipla’s top three products in the US. Cipla disclosed that manufacturing of Lanreotide is being temporarily stopped to support USFDA remediation at the facility producing the drug. Another report said the disruption followed USFDA observations at Pharmathen’s manufacturing facility in Greece, with an inspection conducted from November 10, 2025 to November 21, 2025 resulting in nine Form 483 observations.

Cipla expects resupply to resume in the first half of FY27, with limited availability until manufacturing restarts and quality clearances are secured. One brokerage note cited Lanreotide revenue at about $150 million annually and a 22% market share for the product, underscoring why any extended disruption is closely tracked.

Key figures investors are tracking

Market impact: balancing Ventolin upside with portfolio risk

From a market-impact perspective, the approval is clearly positive for Cipla’s US respiratory portfolio because it adds an AB-rated substitutable inhaler opportunity in a large category. But the stock’s mixed reaction highlights that investors are simultaneously pricing other US factors, particularly the phase-out of gRevlimid exclusivity mentioned in brokerage notes and the Lanreotide supply uncertainty.

Cipla’s US market importance is also visible in its reported numbers. The US market contributed 27% of Cipla’s topline in FY2024-25, with record sales of $134 million, while US sales for the September 2025 quarter were $133 million. Against that backdrop, a new inhaler launch can help, but supply stability in existing key products remains crucial.

Analysis: why execution is still the deciding variable

The Ventolin nod is a regulatory milestone and a proof point on complex inhalation capability, backed by Cipla’s Fall River, Massachusetts inhalation facility. Broker estimates, however, vary widely on revenue contribution, from $10 million to $10 million annually (Citi) to $130 million in FY27 sales (Morgan Stanley), suggesting differing assumptions on pricing and competitive intensity.

The debate is less about whether the product is attractive and more about how smoothly Cipla executes launches and manages other portfolio disruptions. That is why ratings remain split, with some brokerages upgrading or reiterating Buy calls, while others keep cautious stances tied to pipeline delivery and near-term earnings visibility.

Conclusion: approval adds a new lever, but timing matters

Cipla’s final USFDA approval for the first AB-rated generic Ventolin HFA equivalent strengthens its respiratory franchise and sets up a planned H1 FY2026-27 launch into a $1,500 million US market. Still, the stock’s performance suggests investors are weighing that opportunity against the timing of financial impact and parallel risks, especially around Lanreotide supply and broader US portfolio transitions. The next clear catalyst is execution-related: updates on launch preparedness for the inhaler and visibility on Lanreotide resupply, which Cipla expects to resume in H1 FY27.